History of pancreatitis Severe gastrointestinal disease Gallbladder disease or a history of cholelithiasis Pregnancy or breastfeeding Concomitant use of insulin or insulin secretagogues (e.g., sulphonylureas), which may increase hypoglycaemia risk Retatrutide, like other incretin-class medicines, may slow gastric emptying, which can affect the absorption of oral medicines taken at the same time

Key Points The incretins glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) are gut-derived hormones that potentiate insulin secretion and contribute to glucose metabolism through a wide range of physiological actions Inhibitors of the incretin-inactivating enzyme dipeptidyl peptidase 4 (DPP-4) and DPP-4-resistant injectable GLP-1 receptor agonists have been developed for the treatment of hyperglycaemia in type 2 diabetes mellitus (T2DM) GLP-1 and other gut-derived hormones might directly and/or indirectly regulate electrolyte and fluid homeostasis by influencing feeding and drinking behaviour as well as electrolyte transport in the kidneys and gastrointestinal tract GLP-1 receptor (GLP-1R) agonists and DPP-4 inhibitors increase natriuresis in T2DM, possibly through overlapping and distinct mechanisms, and might slightly improve renal haemodynamics in the setting of diabetes-related glomerular hyperfiltration Incretin-based therapies seem to directly influence renal physiology and have indirect metabolic and haemodynamic actions that might reduce renal risk in T2DM

Zhao, R., Chen, Y., Ma, Y., Zou, C., Zhang, J., & Chen, Z
and therefore, we cannot confirm that the CVS formulary change directly caused the shift in prescription trends
Plateauing Results